Sanofi India share news, announcements and annual reports
NSE: SANOFIBSE: 500674Pharmaceuticals & BiotechnologySmall Cap
Sanofi India Limited · Formerly Aventis Pharma · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Oct 1984 on BSE, May 2003 on NSE
Last close ₹3,204.10up ₹14.60 (0.46%)BSE ₹3,204.40
Share price at the NSE close on 30 Oct 2026. Previous close ₹3,189.50.
30 Oct: open ₹3,265.00, high ₹3,422.60, low ₹3,175.10
52-week range of traded prices to 30 Oct 2026
₹2,758.20Low, 23 Oct 2026₹4,834.00High, 30 Oct 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹7,379 Cr614th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 20.24
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 8.93
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 3.84%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 45.3%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 57.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Jun 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 2,04,44220.0% delivered
Sanofi India share news and announcements
701 announcements, routine notices left out, newest first. Page 13 of 15.
Feb 2011
17 Feb · Meeting
Register of Members and Share Transfer Books of the Company will be closed from April 06, 2011 to April 26, 2011 (both days inclusive) for the following purposes: [1] Annual General Meeting to be held on April 26, 2011. [2] Payment of Final Dividend for the year ended December 31, 2010 and Special One-time Dividend recommended by the Board of Directors, if declared at the Annual General Meeting to be held on April 26,2011.16 Feb · Dividend
Board of Directors of the Company at its meeting held on February 16, 2011, inter alia, has recommended: (1) Final Dividend of Rs. 23 per Equity share of Rs. 10 for the year ended December 31, 2010. An Interim dividend of Rs. 4 per Equity share of Rs. 10 had been paid in August 2010. (2) A Special One-time Dividend of Rs. 28 per Equity share of Rs. 10 arising from the profit of the sale of the Company's shareholding in Chiron Behring Vaccines Private Limited.16 Feb · Results
Standalone Results for the year ended on 31-DEC-2010 as follows: Net Sales of Rs. 108500 lacs for year ending on 31-DEC-2010 against Rs. 97440 lacs for the year ending on 31-DEC-2009. Net Profit / (Loss) of Rs. 23070 lacs for the year ending on 31-DEC-2010 against Rs. 15740 lacs for the year ending on 31-DEC-2009.2 Feb · Board meeting
For approving the Audited Accounts for the year ended December 31, 2010 and also to consider recommendation of Final Dividend for the said financial year.
Dec 2010
Nov 2010
Oct 2010
25 Oct · Results
Standalone Results for the quarter ended on 30-SEP-2010 as follows: Net Sales of Rs. 27560 lacs for quarter ending on 30-SEP-2010 against Rs. 25850 lacs for the quarter ending on 30-SEP-2009. Net Profit / (Loss) of Rs. 4730 lacs for the quarter ending on 30-SEP-2010 against Rs. 4380 lacs for the quarter ending on 30-SEP-2009.12 Oct · Board meeting
For approving the Unaudited Financial Results for the quarter and nine months ended September 30, 2010.
Sep 2010
Aug 2010
Jul 2010
19 Jul · Dividend
Board of Directors of the Company at its meeting held on July 19, 2010, declared an Interim Dividend of Rs. 4 per Equity share of Rs. 10 to be paid to those Members whose names appear on the Register of Members of the Company on July 27, 2010, being the Record Date.19 Jul · Results
Standalone Results for the half year ended on 30-JUN-2010 as follows: Net Sales of Rs. 52290 lacs for half year ending on 30-JUN-2010 against Rs. 47880 lacs for the half year ending on 30-JUN-2009. Net Profit / (Loss) of Rs. 7850 lacs for the half year ending on 30-JUN-2010 against Rs. 8760 lacs for the half year ending on 30-JUN-2009.19 Jul · Results
Standalone Results for the quarter ended on 30-JUN-2010 as follows: Net Sales of Rs. 27150 lacs for quarter ending on 30-JUN-2010 against Rs. 24990 lacs for the quarter ending on 30-JUN-2009. Net Profit / (Loss) of Rs. 4240 lacs for the quarter ending on 30-JUN-2010 against Rs. 4710 lacs for the quarter ending on 30-JUN-2009.14 Jul · Corporate action
In case Interim Dividend is declared by the Board at the Board meeting to be held on July 19, 2010, the Record date for the purpose of payment of such Interim dividend will be July 27, 2010.7 Jul · Board meeting
For : a) Approving the Unaudited Financial Results for the quarter and half year ended June 30, 2010 and b) Considering the question of declaring an Interim dividend for the current financial year ending on December 31, 2010.
Jun 2010
Apr 2010
30 Apr · Updates
Speech of the Chairman, Dr Vijay Mallya delivered at the Annual General Meeting held on April 27, 2010. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.27 Apr · Results
Standalone Results for the quarter ended on 31-MAR-2010 as follows: Net Sales of Rs. 25140 lacs for quarter ending on 31-MAR-2010 against Rs. 22890 lacs for the quarter ending on 31-MAR-2009. Net Profit / (Loss) of Rs. 3610 lacs for the quarter ending on 31-MAR-2010 against Rs. 4050 lacs for the quarter ending on 31-MAR-2009.8 Apr · Board meeting
For approving the Unaudited Financial Results for the quarter ended March 31, 2010 (which is the first quarter of the Company's financial year).6 Apr · Meeting
Notice of Annual General Meeting, to be held on April 27, 2010. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Mar 2010
22 Mar · Disclosure
"Hoechst GmbH, a 100% subsidiary of Sanofi-aventis S.A., has decided to increase its equity shareholding in Aventis Pharma Limited by offering to purchase 2,366,380 equity shares representing 10.27% of share capital of Aventis Pharma Limited from other "qualifying promoters" of Aventis Pharma Limited (comprising of United Breweries (Holding) Limited, Kingfisher Finvest India Limited, McDowell Holdings Limited and Mallya Private Limited) as inter-se transfer amongst the qualifying promoters at a price of Rs.1,750/- per equity share. This offer satisfies all the tests prescribed under the SAST Regulations for being regarded as an inter-se transfer amongst the qualifying promoters and is eligible for exemption from an open offer obligation to the minority shareholders of Aventis Pharma Limited". The details of the same shall be available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Feb 2010
25 Feb · Meeting
Register of Members and Share Transfer Books of the Company will be closed from April 09, 2010 to April 27, 2010 (both days inclusive) for the following purposes: [1] Annual General Meeting to be held on April 27, 2010. [2] Payment of Final Dividend for the year ended December 31, 2009, if declared at the Annual General Meeting to be held on April 27, 2010.24 Feb · Dividend
Board of Directors of the company in their meeting held on February 24, 2010 has recommended a final dividend of Rs. 16.50 per share of Rs 10 for the year ended December 31, 2009. An interim dividend of Rs. 3.50 per Equity share of Rs. 10 had been paid in August 2009. The total dividend for the year ended December 31, 2009 is accordingly Rs. 20 per equity share of Rs. 10 (Previous year: Rs. 16 per Equity share). The dividend payout is 29.3% of the Net Profit for the year ended December 31, 2009.24 Feb · Results
Standalone Results for the quarter ended on 31-DEC-2009 as follows: Net Sales of Rs. 23710 lacs for quarter ending on 31-DEC-2009 against Rs. 26990 lacs for the quarter ending on 31-DEC-2008. Net Profit / (Loss) of Rs. 2600 lacs for the quarter ending on 31-DEC-2009 against Rs. 4530 lacs for the quarter ending on 31-DEC-2008.24 Feb · Results
Standalone Results for the year ended on 31-DEC-2009 as follows: Net Sales of Rs. 97440 lacs for year ending on 31-DEC-2009 against Rs. 98330 lacs for the year ending on 31-DEC-2008. Net Profit / (Loss) of Rs. 15740 lacs for the year ending on 31-DEC-2009 against Rs. 16620 lacs for the year ending on 31-DEC-2008.11 Feb · Board meeting
For approving the audited Accounts for the year ended December 31, 2009 and also to consider recommendation of Final Dividend for the said financial year.5 Feb · Disclosure
Aventis Pharma Limited had informed the Exchange regarding disclosures in respect of the reduction in shareholding of 2% in the Company of UTI Mutual Fund consequent on aggregate sale of 505,463 Shares from August 18, 2005 to December 11, 2009. The Company has now informed the Exchange that the figures furnished by the Company in Form C were based on figures furnished to the Company by UTI Mutual Fund. Further, the Company has informed the Exchange that "It has been pointed out to us that the figures given in Form C were not correct. We accordingly took up the matter with UTI Mutual Fund and they have clarified that they had omitted 201 Shares in their disclosures to us". Further, in view of the revised figures furnished by UTI Mutual Fund, the Company has submitted to the Exchange revised Form C. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jan 2010
12 Jan · Results
The financial year of the Company is the period of 12 months from January to December. Under Clause 41 of the Listing Agreement, the Unaudited Financial Results for the last quarter of the financial year need not be published if the Company undertakes to publish the Audited Results for the full year within three months of the close of the financial year. Accordingly, the Company will not publish the Unaudited Financial Results for the quarter ended 31st December 2009 and undertakes to publish the Audited Results for the year ended 31st December 2009 before 31st March 20104 Jan · Disclosure
(1) Disclosure in terms of Regulation 13(6) of the SEBI (Prohibition of Insider Trading) Regulations, 1992; (2) Disclosure in terms of Regulation 7(3) of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 1997. The copies of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Dec 2009
10 Dec · Business
Press release dated December 10, 2009, titled "Sanofi-aventis launches PRAYAS, an endeavor to meet rural India's healthcare needs". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Oct 2009
27 Oct · Results
Standalone Results for the quarter ended on 30-SEP-2009 as follows: Net Sales of Rs. 25850 lacs for quarter ending on 30-SEP-2009 against Rs. 24790 lacs for the quarter ending on 30-SEP-2008. Net Profit / (Loss) of Rs. 4380 lacs for the quarter ending on 30-SEP-2009 against Rs. 4460 lacs for the quarter ending on 30-SEP-2008.14 Oct · Board meeting
For approving the Unaudited Financial Results for the quarter and nine months ended September 30, 2009.
Aug 2009
25 Aug · Management
Mr. Christophe Germain, Chief Financial Officer and Wholetime Director of the Company has been appointed as the Chief Financial Officer of the sanofi-aventis affiliate in South Korea. Mr. Germain has accordingly resigned as Chief Financial Officer and Director of the Company with effect from the close of business hours on 31st July 2009
Jul 2009
28 Jul · Business
Vide its letter dated July 24, 2009 regarding a press release issued by sanofi-aventis of France (the ultimate holding company of the Company), dated July 23, 2009, titled "CHMP confirms the safety of Lantus ". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.22 Jul · Dividend
Board of Directors, at their meeting held on July 22, 2009 has declared an Interim Dividend of Rs. 3.50 per Equity share of Rs.10 each.22 Jul · Results
Standalone Results for the half year ended on 30-JUN-2009 as follows: Net Sales of Rs. 47880 lacs for half year ending on 30-JUN-2009 against Rs. 46550 lacs for the half year ending on 30-JUN-2008. Net Profit / (Loss) of Rs. 8760 lacs for the half year ending on 30-JUN-2009 against Rs. 7630 lacs for the half year ending on 30-JUN-2008.22 Jul · Results
Standalone Results for the quarter ended on 30-JUN-2009 as follows: Net Sales of Rs. 24990 lacs for quarter ending on 30-JUN-2009 against Rs. 24860 lacs for the quarter ending on 30-JUN-2008. Net Profit / (Loss) of Rs. 4710 lacs for the quarter ending on 30-JUN-2009 against Rs. 4180 lacs for the quarter ending on 30-JUN-2008.21 Jul · Corporate action
In case Interim Dividend is declared by the Board at the Meeting to be held on July 22, 2009 the Record Date for the purpose of payment of such Interim Dividend will be July 31, 2009.17 Jul · Business
Vide its letter dated July 16, 2009 regarding a press release issued by sanofi-aventis of France (the ultimate holding company of the Company), dated July 15, 2009, titled "Expert Statement Issued about Lantus following recent publications in Diabetologia". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.9 Jul · Board meeting
For : a) Approving the Unaudited Financial Results for the quarter and half year ended June 30, 2009 and b) Considering the question of declaring an Interim dividend for the current financial year ending on December 31, 2009.
Jun 2009
30 Jun · Business
Vide its letter dated June 30, 2009 regarding a press release issued by sanofi-aventis of France (the ultimate holding company of the Company), dated June 26, 2009, titled "Sanofi-aventis stands behind the safety of Lantus ". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
May 2009
29 May · Meeting
Minutes of the proceedings of the Annual General Meeting of the members of the Company held on April 28, 2009. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.20 May · Limited Review Report
Auditors have conducted the limited review for the un-audited financial results for the quarter ended March 31, 2009. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Apr 2009
29 Apr · Updates
Speech of the Chairman, Dr. Vijay Mallya delivered at the Annual General Meeting held on April 28, 2009. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.28 Apr · Results
Standalone Results for the quarter ended on 31-MAR-2009 as follows: Net Sales of Rs. 22890 lacs for quarter ending on 31-MAR-2009 against Rs. 21690 lacs for the quarter ending on 31-MAR-2008. Net Profit / (Loss) of Rs. 4050 lacs for the quarter ending on 31-MAR-2009 against Rs. 3450 lacs for the quarter ending on 31-MAR-2008.